Safety and immunogenicity of a new heat-inactivated hepatitis B virus vaccine in adult recipients.
A new heat inactivated HBV vaccine has been evaluated for safety and immunogenicity in 203 adult recipients. The vaccine was found to be safe and highly immunogenic. Three doses of 3 micrograms given at 0, 1 and 6 months, resulted in 96% seroconversion. Three doses of 3 micrograms given at 0, 1 and 2 months produced, more rapidly, seroconversion in 92% of those immunized. Antibody to a pre-S determinant developed in four of six subjects tested.
Chung
W K
WK
Department of Internal Medicine, St. Mary's Hospital, Catholic Medical Center, Seoul, Korea.
Sun
H S
HS
Chung
K W
KW
Kim
B S
BS
Min
B K
BK
Prince
A M
AM
D000328:Adult; D004306:Dose-Response Relationship, Immunologic; D005069:Evaluation Studies as Topic; D005260:Female; D006509:Hepatitis B / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000096:biosynthesis; D006358:Hot Temperature; D006801:Humans; D007114:Immunization / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D014613:Vaccines, Attenuated; D014761:Viral Hepatitis Vaccines / Q000592:standards*
D006510:Hepatitis B Antibodies; D014613:Vaccines, Attenuated; D014761:Viral Hepatitis Vaccines